Enoxaparin as Treatment for Vulvar Vestibulitis Syndrome - Vulvodynia.

Trial Profile

Enoxaparin as Treatment for Vulvar Vestibulitis Syndrome - Vulvodynia.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2012

At a glance

  • Drugs Enoxaparin sodium (Primary)
  • Indications Dyspareunia; Embolism and thrombosis; Vulvar vestibulitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Sep 2012 Primary endpoint 'Pain-intensity' has been met according to results published in Obstetrics and Gynecology.
    • 01 Sep 2012 Results published in Obstetrics and Gynecology.
    • 17 Oct 2011 Planned end date changed from 1 May 2012 to 1 May 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top